Inhibition of these processes with EGFR inhibitors decreases TRPM6 activity and reduces Mg2+ influx into cells, promoting Mg2+ excretion in the kidney with resultant Mg2+ wasting and hypomagnesemia. The gene discussed is EGFR; the disease is familial primary hypomagnesemia.